ライフサイエンスコーパス: vaginal bleeding

1 r uterine segment with a history of painless vaginal bleeding.

2 differential diagnosis of sudden and massive vaginal bleeding.

3 dergoing pelvic scans for reasons other than vaginal bleeding.

4 ogic evaluation in postmenopausal women with vaginal bleeding.

5 ynecologic follow-up for persistent abnormal vaginal bleeding.

6 transient hemorrhagic cystitis (1 patient), vaginal bleeding (2 patients), gastrointestinal bleeding

7 women in the hormone group who did not have vaginal bleeding (3.8+/-4.3 vs. 0.7+/-1.5 nodes, P=0.006

8 rasound images obtained in 516 patients with vaginal bleeding, a live fetus, and a subchorionic hemat

9 ominal pain, nausea, vomiting, diarrhea, and vaginal bleeding also increased with advancing gestation

10 DHT altered the duration of vaginal bleeding and delayed restoration of the luminal

11 The overall association between vaginal bleeding and preterm birth was modest (risk rati

12 a 46-year-old lady who presented with heavy vaginal bleeding and ultrasound/colour Doppler evidence

13 teoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less fre

14 amnionitis, maternal antibiotics, antepartum vaginal bleeding, and labor lasting less than 4 hours.

15 likely to produce weight gain, dyspnea, and vaginal bleeding, and the letrozole groups were more lik

16 w-dose aspirin was associated with increased vaginal bleeding, but this adverse event was not associa

17 Patients may present with vaginal bleeding caused by endometrial hyperplasia or ut

18 Vaginal bleeding events were defined as any vaginal bleeding complications as reported by the patien

19 o investigate the management and outcomes of vaginal bleeding complications during therapy with direc

20 vide guidance on prevention and treatment of vaginal bleeding complications in this patient populatio

21 ively, but patients with severe or recurrent vaginal bleeding complications should be assessed for un

22 The presence of abdominal pain or vaginal bleeding during early pregnancy should prompt a

23 estigated the relation between self-reported vaginal bleeding during pregnancy and preterm birth in a

24 Vaginal bleeding events were defined as any vaginal blee

25 factor Xa inhibitor therapy, of whom 57 had vaginal bleeding events, including 50 who received rivar

26 These 57 women had 72 vaginal bleeding events, including 59 cases of heavy men

27 and mortality; and pattern and management of vaginal bleeding events.

28 rovided daily urine specimens and records of vaginal bleeding for up to 1 year or until clinical preg

29 rovided daily urine specimens and records of vaginal bleeding for up to 1 year or until clinical preg

30 rning urine specimens and recorded days with vaginal bleeding for up to 6 months.

31 n of endometrial biopsies required to assess vaginal bleeding further limits the acceptability of thi

32 , women in the hormone group with antecedent vaginal bleeding had colorectal cancers with a greater n

33 sulted in abdominal pain in 73% of women and vaginal bleeding in 32% compared with 3% and 0%, respect

34 Associations with antepartum vaginal bleeding (increased risk) and preeclampsia (decr

35 Postmenopausal vaginal bleeding is a common clinical problem.

36 There were no significant differences in vaginal bleeding, mood alteration, or low energy.

37 nemia (n = 2), other cardiovascular (n = 2), vaginal bleeding (n = 1), neutropenia (n = 1), and fistu

38 Raloxifene did not cause vaginal bleeding or breast pain and was associated with

39 ents with uterine LMS typically present with vaginal bleeding, pain, and a pelvic mass.

40 Vaginal bleeding, particularly heavy menstrual bleeding,

41 Knowing the expected vaginal bleeding pattern for each hormone replacement th

42 peri- and postmenopausal women with abnormal vaginal bleeding seen in clinical practice.

43 r maternal age, smoking, and first-trimester vaginal bleeding, standard guidelines for adjudicating d

44 r more pregnant women with abdominal pain or vaginal bleeding that evaluated patient history, physica

45 One woman had minimal vaginal bleeding; there were no adverse events.

46 Baseline symptom prevalence ranged from 2% (vaginal bleeding) to 60% to 70% (bone/muscle aches and l

47 om timed matings of FG(-/-) mice showed that vaginal bleeding was initiated as early as embryonic day

48 Vaginal bleeding was not associated with preterm birth a

49 Breast tenderness and atypical vaginal bleeding were the most frequently reported adver

50 ; to features of congestive heart failure to vaginal bleeding which may at times life be threatening.

51 reliably identify postmenopausal women with vaginal bleeding who are highly unlikely to have signifi

52 For a postmenopausal woman with vaginal bleeding with a 10% pretest probability of endom

53 he/visual disturbances; chest pain/dyspnoea; vaginal bleeding with abdominal pain; systolic blood pre

54 DUB is defined as abnormal vaginal bleeding without an identifiable pathologic cond